In collaboration with Datar Cancer Genetics, Apollo Cancer Centres has released a test for the early diagnosis of breast cancer.

On Wednesday, Apollo Cancer Centres, which is a part of the Apollo Hospitals NSE -0.31 percent group and is working in an exclusive partnership with Datar Cancer Genetics, announced the launch of a blood test that can detect breast cancers at early stages in asymptomatic individuals with a high level of accuracy.

By taking a little blood sample, the screening test known as EasyCheck-Breast can assist in the early diagnosis of breast cancer, even before the disease has reached the first stage.

The EasyCheck-Breast test, which was created by Datar Cancer Genetics, a molecular diagnostics firm located in Nashik, has been granted breakthrough designation status by the US Food and Drug Administration (USFDA) and has also been authorised by the United Kingdom and Europe. The purpose of the test is to determine whether or not breast adenocarcinoma cancer tumour cells are present in the blood.

In clinical studies, the EasyCheck-Breast was evaluated on 8112 asymptomatic women who had a baseline cancer risk and BIRADS-1 on mammography, in addition to 217 women who were already diagnosed with breast cancer. The results of the test indicated that the sensitivity was 99 percent, while both the specificity and accuracy were at 88.2 percent.

Women who are at least 40 years old and have no symptoms are encouraged to have the test after consulting with a trained medical professional.

The examination will cost around 6000 Indian Rupees.

The self-breast inspection, clinical breast examination, mammography, and ultrasound screening options for breast cancer detection that are currently on the market will be supplemented with the new test.

“In accordance with our mission to educate people about the importance of early cancer detection and to provide world-class cancer treatment, we are pleased to announce the launch of EasyCheck Breast, which marks an important success toward the development of high-quality technological innovations that will ensure prompt diagnosis and treatment in order to reduce the mortality rate “Dr. Prathap Reddy, founder and chairman of Apollo Hospitals, made this statement.

Reddy went on to say that “this cooperation with Datar Cancer Genetics has created a path-breaking breakthrough,” and that “at Apollo Cancer Centres, we are fully equipped to identify breast tumours with the best-in-class technologies and therapies.”

“Unfortunately, most tumours are identified at advanced stages, which necessitates more extensive and expensive therapies. These medicines also have a larger chance of devastating side effects and treatment failures.” EasyCheck-Breast is the product of years of collective effort and innovation on a global scale. It has been developed, tested, and validated on population-sized cohorts, and it has been shown to be accurate in detecting breast cancer “Rajan Datar, founder and chairman of Datar Cancer Genetics, is quoted as saying something.

Worldwide, the majority of women are diagnosed with breast cancer as their first malignancy. It is currently expected to be the top cause of cancer incidence worldwide in the year 2020, surpassing lung cancer as the leading cause by an estimated 2.3 million new cases, which accounts for 11.7 percent of all cancer cases. Epidemiological research have showed that the worldwide burden of breast cancer is anticipated to exceed about 2 million by the year 2030. This number is predicted to be reached by the year 2030. According to the available information, breast cancer was responsible for 13.5 percent (178361) of all cases of cancer and 10.6 percent (90408) of all fatalities in India in the year 2020.

Leave a Comment